HeartBeam Named “Rising Star” at the 6th Annual Digital Health Hub Foundation Awards
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 24 2024
0mins
Should l Buy BEAT?
Source: Businesswire
HeartBeam's Award Recognition: HeartBeam, Inc. has won the Rising Star award in the 'Home Health Diagnostic' category at the 2024 Digital Health Hub Awards for its innovative approach to cardiac care, which includes a cable-free device capable of synthesizing a 12-lead ECG.
Technological Innovation: The company's vector-based technology captures heart electrical signals in three dimensions and utilizes AI for analysis, aiming to provide personalized cardiac insights and improve timely patient care outside of medical facilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BEAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BEAT
Wall Street analysts forecast BEAT stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.871
Low
4.00
Averages
5.83
High
8.00
Current: 0.871
Low
4.00
Averages
5.83
High
8.00
About BEAT
HeartBeam, Inc. is a cardiac technology company. The Company focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. It is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. It is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atelier Health Partners with HeartBeam to Expand Cardiac Care
- Market Expansion: The commercial agreement between Atelier Health and HeartBeam signifies the completion of HeartBeam's flagship market presence across New York, Dallas, South Florida, and Southern California, enhancing its penetration in the preventive cardiology sector.
- Technological Innovation: HeartBeam's 3D ECG technology, which received FDA clearance, enables high-fidelity ECG data collection at home, enhancing patients' proactive monitoring capabilities and promoting the adoption of personalized healthcare services.
- Business Model Validation: This partnership not only advances HeartBeam's subscription-based business model but also accelerates technology adoption in high-value direct-pay healthcare environments through collaboration with leading medical practices.
- Strategic Collaboration: The expansion of Atelier Health aligns with HeartBeam's market strategy, as both entities aim to deliver personalized preventive and diagnostic programs, thereby enhancing patient care experiences and health management outcomes.
See More
HEARTBEAM INC LAUNCHES FLAGSHIP LOCATIONS IN NEW YORK, DALLAS, SOUTH FLORIDA, AND SOUTHERN CALIFORNIA
- New Locations: HeartBeam Inc. has opened flagship sites in New York, Dallas, South Florida, and Southern California.
- Expansion Strategy: The company aims to enhance its presence and accessibility in key markets across the United States.
See More
HeartBeam to Host Q1 2026 Earnings Call on May 13
- Earnings Call Schedule: HeartBeam will hold its earnings call on May 13, 2026, at 4:30 PM ET to discuss Q1 results ending March 31, 2026, and update on key strategic growth initiatives, which is expected to positively impact investor confidence.
- Strategic Growth Initiatives: The call will highlight the company's limited commercial launch for arrhythmia assessment and developments in its extended-wear patch, heart attack detection, and AI initiatives, showcasing its innovative capabilities and market potential in cardiac health management.
- Technological Innovation and FDA Approval: HeartBeam has developed the first-ever cable-free device capable of collecting 3D ECG signals from three non-coplanar directions, receiving FDA clearance for arrhythmia assessment in December 2024, marking a significant breakthrough in cardiac monitoring technology.
- Investor Relations and Information Access: The call will feature a webcast, allowing investors to access materials and replay information through the company's website, enhancing communication and transparency between the company and its investors.
See More
HeartBeam Prices Public Offering to Raise $10 Million
- Offering Size: HeartBeam priced its public offering at $0.80 per share for a total of 12.5 million shares, aiming to raise $10 million, which indicates the company's ability to access capital markets but also reflects investor concerns about its stock price.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 1.875 million shares, providing flexibility that could offer further funding support while potentially impacting market liquidity expectations for the stock.
- Use of Proceeds: The net proceeds will fund the commercialization of its FDA-cleared 12-lead synthesized ECG system, development of an extended-wear patch, and AI enhancements for heart attack detection tools, highlighting the company's strategic focus on innovation in cardiac health.
- Stock Price Movement: Following the offering announcement, HeartBeam's stock price declined approximately 12% in after-hours trading on Tuesday, reflecting cautious investor sentiment regarding the company's future prospects, which may affect its subsequent financing and market confidence.
See More
HeartBeam Initiates Underwritten Public Offering of Common Stock
- Offering Launch: HeartBeam announced the commencement of an underwritten public offering of its common stock, with all shares being issued and sold by the company, indicating a proactive approach to financing amid market conditions.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized to launch and grow its FDA-approved ECG system, develop an extended-wear patch, support heart attack detection initiatives, and enhance AI capabilities, demonstrating the company's commitment to technological innovation.
- Market Reaction: Despite HeartBeam closing flat at $1.20 during regular trading, it fell to $0.98 in after-hours trading, down approximately 18.33%, reflecting a cautious market sentiment regarding the financing initiative.
- Underwriter Selection: Titan Partners has been appointed as the sole bookrunner for the offering, showcasing the company's strategic considerations in partner selection to ensure a smooth financing process.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
- Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
- Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
See More
Atelier Health Partners with HeartBeam to Expand Cardiac Care
- Market Expansion: The commercial agreement between Atelier Health and HeartBeam signifies the completion of HeartBeam's flagship market presence across New York, Dallas, South Florida, and Southern California, enhancing its penetration in the preventive cardiology sector.
- Technological Innovation: HeartBeam's 3D ECG technology, which received FDA clearance, enables high-fidelity ECG data collection at home, enhancing patients' proactive monitoring capabilities and promoting the adoption of personalized healthcare services.
- Business Model Validation: This partnership not only advances HeartBeam's subscription-based business model but also accelerates technology adoption in high-value direct-pay healthcare environments through collaboration with leading medical practices.
- Strategic Collaboration: The expansion of Atelier Health aligns with HeartBeam's market strategy, as both entities aim to deliver personalized preventive and diagnostic programs, thereby enhancing patient care experiences and health management outcomes.
See More
HEARTBEAM INC LAUNCHES FLAGSHIP LOCATIONS IN NEW YORK, DALLAS, SOUTH FLORIDA, AND SOUTHERN CALIFORNIA
- New Locations: HeartBeam Inc. has opened flagship sites in New York, Dallas, South Florida, and Southern California.
- Expansion Strategy: The company aims to enhance its presence and accessibility in key markets across the United States.
See More
HeartBeam to Host Q1 2026 Earnings Call on May 13
- Earnings Call Schedule: HeartBeam will hold its earnings call on May 13, 2026, at 4:30 PM ET to discuss Q1 results ending March 31, 2026, and update on key strategic growth initiatives, which is expected to positively impact investor confidence.
- Strategic Growth Initiatives: The call will highlight the company's limited commercial launch for arrhythmia assessment and developments in its extended-wear patch, heart attack detection, and AI initiatives, showcasing its innovative capabilities and market potential in cardiac health management.
- Technological Innovation and FDA Approval: HeartBeam has developed the first-ever cable-free device capable of collecting 3D ECG signals from three non-coplanar directions, receiving FDA clearance for arrhythmia assessment in December 2024, marking a significant breakthrough in cardiac monitoring technology.
- Investor Relations and Information Access: The call will feature a webcast, allowing investors to access materials and replay information through the company's website, enhancing communication and transparency between the company and its investors.
See More
HeartBeam Prices Public Offering to Raise $10 Million
- Offering Size: HeartBeam priced its public offering at $0.80 per share for a total of 12.5 million shares, aiming to raise $10 million, which indicates the company's ability to access capital markets but also reflects investor concerns about its stock price.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 1.875 million shares, providing flexibility that could offer further funding support while potentially impacting market liquidity expectations for the stock.
- Use of Proceeds: The net proceeds will fund the commercialization of its FDA-cleared 12-lead synthesized ECG system, development of an extended-wear patch, and AI enhancements for heart attack detection tools, highlighting the company's strategic focus on innovation in cardiac health.
- Stock Price Movement: Following the offering announcement, HeartBeam's stock price declined approximately 12% in after-hours trading on Tuesday, reflecting cautious investor sentiment regarding the company's future prospects, which may affect its subsequent financing and market confidence.
See More
HeartBeam Initiates Underwritten Public Offering of Common Stock
- Offering Launch: HeartBeam announced the commencement of an underwritten public offering of its common stock, with all shares being issued and sold by the company, indicating a proactive approach to financing amid market conditions.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized to launch and grow its FDA-approved ECG system, develop an extended-wear patch, support heart attack detection initiatives, and enhance AI capabilities, demonstrating the company's commitment to technological innovation.
- Market Reaction: Despite HeartBeam closing flat at $1.20 during regular trading, it fell to $0.98 in after-hours trading, down approximately 18.33%, reflecting a cautious market sentiment regarding the financing initiative.
- Underwriter Selection: Titan Partners has been appointed as the sole bookrunner for the offering, showcasing the company's strategic considerations in partner selection to ensure a smooth financing process.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
- Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
- Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
See More
